Worldwide Healthcare (Ordinary Share) WWH

Sector Specialist: Biotechnology/Life Sciences

Register or Sign in to receive email alerts for items in your favourites whenever we write about them

Add to Virtual Portfolio | Print page

Estimated NAV (p)

1265.00

Share Price (p)

1216.61

Total Returns on £1000 over 

Fund / Benchmark Total returns(%)
Worldwide Healthcare (Ordinary Share) Price 82.29%
Worldwide Healthcare (Ordinary Share) NAV 75.30%
FTSE World 27.34%
Total Returns on £1000

Discount / Premium Movement

Discount / Premium Movement

Shares

Share Type Yesterday's
Closing Price
Discount / Premium Diluted NAV Gearing Dividend
Est Last
Ordinary Share 1202.0p -5.0% 1265.00p 1246.00p
15 Apr
111% 1.37%

Discrete performance % over

Fund / BenchmarkMay '11
Apr '12
May '12
Apr '13
May '13
Apr '14
Worldwide Healthcare (Ordinary Share) Price12.8336.5518.31
Worldwide Healthcare (Ordinary Share) NAV10.4535.5917.06
FTSE World-0.7219.886.99

Discrete performance over

Discrete Performance

Top 10 Holdings

Roche Holding AG 6.67%
Gilead Sciences Inc 4.12%
Regeneron Pharmaceuticals, Inc. 3.93%
MYLAN 3.63%
Merck & Co. Inc. 3.24%
HCA Holdings Inc 3.24%
Bristol-Myers Squibb Company 3.04%
Biogen Idec Inc., 2.94%
Amgen Inc 2.94%
Incyte Genomics 2.85%

Sectors weighting

Pharmaceuticals 101.80%
General Equity 0.50%
Net Current Assets -2.30%

Regional weighting

North America Region 81.00%
Europe Developed ex-UK 11.00%
Japan 7.00%
Other Countries 3.00%
Asia exc Japan 0.00%
  • Investment trust info:

  • Sector Sector Specialist: Biotechnology/Life Sciences
  • Launch Date 28 Apr 1995
  • Base Currency GBX
  • Domicile UK
  • Share Price (p) 1216.61
  • Share Type Ordinary Share
  • TIDM WWH
  • ISIN GB0003385308
  • Shares Issued (M) 46
  • Market Capital (£M) 556.43
  • Gross Assets (£M) 658.86
  • Net Assets (£M) 596.13
  • TER (%) 0.73
  • Historic Dividend Yield (%) 1.37
  • Next Dividend Date 04 Jun 2014
  • Next Dividend (p) 7.00
  • Last AGM 17 Jul 2013
  • Next AGM 17 Jul 2014
  • Last Annual Report Date 21 Jun 2013
  • Next due Report Date  
  • Next due Report Type I/R
  • Objective:

  • To invest worldwide in pharmaceutical and biotechnology companies with the aim of achieving a high level of capital growth.
  • Management Group(s):

  • Frostrow Capital LLP
  • OrbiMed Capital LLC
  • OrbiMed Capital LLC
  • Managed by:

  • Alastair Smith Start: 10 Apr 2007
  • Samuel. D Isaly Start: 26 Feb 2009
  • Management Contract & Fees:

    The Manager receives a periodic fee equal to 0.30% p.a. of the Company's market capitalization up to GBP150m, 0.20% p.a. of the market capitalization in excess of GBP150m and up to GBP500m, and 0.125% p.a. of the market capitalization in excess of GBP500m, plus a fixed amount equal to GBP 57,500 per annum. The notice period on the Management, Administration and Company Secretarial Agreement with Frostrow is 12 months, termination can be initiated by either party. Investment Manager is also entitled to the payment of a performance fee. The performance fee amounts to 16.5% of any out-performance of the NAV over the benchmark index. At each quarterly calculation date any performance fee payable is based on the lower of: (i) the cumulative out-performance of the investment portfolio over the benchmark index as at the quarter end date; and (ii) the cumulative out-performance of the investment portfolio over the benchmark as at the corresponding quarter end date in the previous year.

Sorry, this link is not
quite ready yet